Zantac (ranitidine) was pulled from the market in 2020 after testing showed it could degrade into NDMA — a probable human carcinogen. Litigation continues in state courts alleging long-term users developed cancer.
Zantac (ranitidine) was one of the best-selling heartburn medications in history. In 2019, independent laboratory testing found that ranitidine could degrade into NDMA — a probable human carcinogen — during storage and possibly inside the body. The FDA requested a complete market withdrawal in April 2020.
Thousands of lawsuits allege long-term Zantac users developed cancers — bladder, stomach, liver, pancreatic, colorectal, and others — and that manufacturers knew or should have known about the NDMA formation risk for decades.
The federal MDL was dismissed in 2022 after the court excluded plaintiffs' expert testimony, but litigation continues in state courts — including coordinated proceedings in Delaware and California — where claims proceed under state-court evidentiary standards.
The federal MDL was dismissed on evidentiary grounds, but state-court litigation remains active — particularly in Delaware and California — and manufacturers have reached settlements in some cases. Claims continue to be evaluated under state-court standards.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Zantac campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Zantac (Ranitidine) Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.